Knight Therapeutics | GUD - Current Liabilities


Knight Therapeutics reported CAD165.26M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acasti Pharma USD 1.28M 39K Dec/2025
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Avita Medical AUD 62.68M 77K Dec/2025
Canopy Growth CAD 158.44M 60.15M Mar/2026
Cronos Group USD 42.42M 5.77M Mar/2026
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Moderna USD 2.4B 408M Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Organigram Holdings CAD 88.74M 5.31M Mar/2026
Organon & Co USD 2.5B 110M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 6.81B 284M Mar/2026
Xeris Pharmaceuticals USD 118.59M 9.02M Mar/2026